Skip to content

The utility of blood-based biomarkers for Alzheimer*s disease in memory Clinic

The utility of blood-based biomarkers for Alzheimer*s disease in memory Clinic - Blood-based biomarkers in AD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51700
Enrollment
400
Registered
2022-11-16
Start date
2023-04-04
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitieve impairment Dementia

Interventions

None listed

Sponsors

Medisch Centrum Leeuwarden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: The patient has to have cognitive complaints or behavioral change and has to be referred from the GP to the memory clinic.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: 1) age under 50 2) known alcohol abuse in the past or present 3) Incapacitated patients

Design outcomes

Primary

MeasureTime frame
The main outcome measure is: 1) Agreement will be calculated between plasma biomarkers for AD and clinical diagnosis at baseline and at follow up (1 year). Working diagnosis Diagnoses of probable AD will be made according to the core clinical criteria of the National Institute on Aging-Alzheimer*s Association (NIA-AA) workgroups.

Secondary

MeasureTime frame
Information for descriptive statistics, if present, will be collected (Disease stage, reported cognitive complains, impairment daily living, cranial MRI result and CSF results). There are no other secondary outcomes.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)